As per the agreement, GSK will pay research funding as well as a sum of $20m as an upfront payment to Epizyme.
Additionally, GSK is also responsible to pay a sum of more than $630m in total milestone payments if medicines are commercialized for all targets in the collaboration.
Epizyme will be primarily responsible for research up to development candidate selection, and GSK will be solely responsible for development and commercialization.
Epizyme president and CEO Robert Gould said that Epizyme’s mission is to develop personalized therapeutics for genetically-defined patients based on their understanding of the driving role played by many HMTs in human disease.
"This collaboration validates our discovery platform and the targeted approach we bring to HMT therapeutics," Gould said.